Toshiyuki Sakaeda

Toshiyuki Sakaeda


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in International Journal of Medical Sciences
Verified
Journal Article
Open access
YIYukako Ito
Yukako Ito
YIYuto Inagaki
Yuto Inagaki
SKShinji Kobuchi
Shinji Kobuchi
KTKanji Takada
Kanji Takada
TSToshiyuki Sakaeda
Toshiyuki Sakaeda
Objective: To design an alternative painless method for vancomycin (VCM) monitoring by withdrawing interstitial fluid (ISF) the skin using dissolving microneedles (DMNs) and possibly replace the conventional clinical blood sampling method.


1 January 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SKShinji Kobuchi
Shinji Kobuchi
YYYukiko Yazaki
Yukiko Yazaki
YIYukako Ito
Yukako Ito
TSToshiyuki Sakaeda
Toshiyuki Sakaeda

22 April 2020 in Antibiotics
Verified
Journal Article
Open access
PDF file
SKShinji Kobuchi
Shinji Kobuchi
TKTeruhiko Kabata
Teruhiko Kabata
KMKoki Maeda
Koki Maeda
YIYukako Ito
Yukako Ito
TSToshiyuki Sakaeda
Toshiyuki Sakaeda
Recent research has found higher levels and longer total exposure of azithromycin, a macrolide antibiotic agent, in the interstitial fluid of the skin than in the plasma. This unique distribution is expected to contribute to its antimicrobial activity at the primary infection site. However, it remains unclear whether this characteristic distribution in the extracellular tissue space is common to macrolide antibiotics or if it is azithromycin-specific, with most macrolides largely localized intracellularly. In this study, we investigated pharmacokinetic characteristics of erythromycin and clarithromycin in the interstitial fluid of the skin of rats after intravenous drug administration, and compared the results with our previously reported results on azithromycin. Interstitial fluid samples were directly collected from a pore on the skin using a dissolving microneedle array. We found that the total macrolide concentrations in the interstitial fluid were significantly different among three macrolides. The rank order of the interstitial fluid-plasma concentration ratio was azithromycin (3.8 to 4.9) > clarithromycin (1.2 to 1.5) > erythromycin (0.27 to 0.39), and this ratio was stable after dosing, whereas higher drug levels in the skin tissue than in the plasma were observed for all three macrolides. Our results suggest that lower erythromycin concentrations in the interstitial fluid than in the plasma contributes to the emergence of bacterial resistance in the extracellular tissue space. Monitoring of total macrolide concentrations in interstitial fluid may provide valuable information regarding antimicrobial effects and the emergence of bacterial resistance for the development of an appropriate pharmacokinetics–pharmacodynamics-based dosing strategy.

1 October 2018 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
SKShinji Kobuchi
Shinji Kobuchi
YIYukako Ito
Yukako Ito
DTDaiki Takamatsu
Daiki Takamatsu
TSToshiyuki Sakaeda
Toshiyuki Sakaeda

29 August 2019 in Xenobiotica
Verified
Journal Article
Closed access
SKShinji Kobuchi
Shinji Kobuchi
AFAkihiro Fujita
Akihiro Fujita
AKAkihito Kato
Akihito Kato
HKHiromu Kobayashi
Hiromu Kobayashi
YIYukako Ito
Yukako Ito
TSToshiyuki Sakaeda
Toshiyuki Sakaeda
1. Recent studies have shown azithromycin-specific clinical efficacy against macrolide-resistant strains of Streptococcus pneumoniae, despite the low susceptibility of the bacteria in vitro. This discrepancy complicates dosing and selection for treatment of macrolide-resistant strains. Although phagocyte delivery of azithromycin to inflamed tissues is considered a possible factor for clinical efficacy, there is a lack of sufficient evidence, and other pharmacokinetic factors under systemic inflammation may contribute. 2. The concentrations of azithromycin, clarithromycin, and erythromycin in the plasma and buffy coat were determined in normal and sepsis model rats. Furthermore, we compared the transport of the drug into the lung. 3. The levels of all three macrolides in the buffy coat were higher than the levels in the plasma, and lower leukocyte counts in plasma were observed in septic rats, suggesting accumulation of the drugs per leukocyte was increased. The concentrations in the lung tissue of septic rats at each sampling time were the same as those in normal rats, and azithromycin-specific long-term stasis in the lung was evident. 4. These results suggest that both the phagocyte delivery and the stasis of azithromycin in the lung could contribute to its clinical efficacy in treating infections caused by macrolide-resistant strains.